An Open-Label, Phase Ib Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
Latest Information Update: 17 Dec 2023
At a glance
- Drugs Trametinib (Primary) ; Docetaxel; Filgrastim
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 25 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 12 Sep 2013 New trial record